Free Trial
ETR:AFX

Carl Zeiss Meditec (AFX) Stock Price, News & Analysis

Carl Zeiss Meditec logo
€45.80 0.00 (0.00%)
(As of 12/20/2024 ET)

About Carl Zeiss Meditec Stock (ETR:AFX)

Key Stats

Today's Range
€45.02
€46.10
50-Day Range
€45.80
€66.40
52-Week Range
€54.60
€123.75
Volume
358,322 shs
Average Volume
94,405 shs
Market Capitalization
$4.10 billion
P/E Ratio
20.09
Dividend Yield
2.40%
Price Target
N/A
Consensus Rating
N/A

Company Overview

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.

Receive AFX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Carl Zeiss Meditec and its competitors with MarketBeat's FREE daily newsletter.

AFX Stock News Headlines

AI breakthrough about to upend industry
Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.
UBS Keeps Their Hold Rating on Carl Zeiss Meditec (0DHC)
Carl Zeiss Meditec AG (AFX.SG)
See More Headlines

AFX Stock Analysis - Frequently Asked Questions

Carl Zeiss Meditec's stock was trading at €98.84 at the start of the year. Since then, AFX shares have decreased by 53.7% and is now trading at €45.80.
View the best growth stocks for 2024 here
.

Based on aggregate information from My MarketBeat watchlists, some other companies that Carl Zeiss Meditec investors own include Intel (INTC), Meta Platforms (META), NVIDIA (NVDA), Volkswagen (VOW3), AbbVie (ABBV), Chevron (CVX) and Siemens Aktiengesellschaft (SIE).

Industry, Sector and Symbol

Sector
Medical
Industry
Medical Instruments & Supplies
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
4,950
Year Founded
N/A

Profitability

Net Income
$203.20 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$2.07 billion
Cash Flow
€0.03 per share
Book Value
€23.42 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.10 billion
Optionable
Not Optionable
Beta
0.98
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

This page (ETR:AFX) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners